New findings from G. Walker and co-researchers in the area of pharmacodynamics described

According to a study from the United States, "WHAT IS ALRADY KNOWN ABOUT THIS SUBJECT center dot Warfarin anticoagulation therapy is commonly administered to patients with pulmonary arterial hypertension (PAH) to reduce the risk of thrombosis and embolism. center dot Ambrisentan is an orally active, propanoic acid-based endothelin receptor antagonist that is likely to be co-administered with warfarin to PAH patients. center dot Concomitant therapies that induce or inhibit warfarin metabolism may alter the systemic exposure of warfarin and significantly alter clotting time, as measured by prothrombin time and International Normalized Ratio, thereby requiring substantial adjustments to...

Want to see the full article?

• Purchase this article for only $3.00